Susan Marie Lang, MD

Articles by Susan Marie Lang, MD

Dr Lang on Ocular Toxicities Following ADC Treatment in Ovarian Cancer

February 9th 2024

Susan Marie Lang, MD, discusses the incidence of ocular toxicity following treatment with mirvetuximab soravtansine in ovarian cancer.

Dr Lang on the Association Between Mirvetuximab Soravtansine and Ocular Toxicity in Ovarian Cancer

BySusan Marie Lang, MD

January 26th 2024

Susan Marie Lang, MD, discusses the incidence of real-world ocular toxicity during treatment with mirvetuximab soravtansine in pretreated ovarian cancer.

Latest Updated Articles

Dr Lang on the Association Between Mirvetuximab Soravtansine and Ocular Toxicity in Ovarian Cancer
January 26th 2024

Susan Marie Lang, MD

Articles by Susan Marie Lang, MD

Dr Lang on Ocular Toxicities Following ADC Treatment in Ovarian Cancer

Dr Lang on the Association Between Mirvetuximab Soravtansine and Ocular Toxicity in Ovarian Cancer

Latest Updated Articles

Trending on OncLive

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC

MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma

Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis

FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC

CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL